Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLUSF BELLUS Health		$9.77	$0.49 ▼ $2.60	$2.35B	1.55	39,610 shs	3.45 million shs
KPTI Karyopharm Therapeutics	$4.77 +4.8%	$4.77	$3.51 ▼ $16.95	$41.21M	0.24	84,920 shs	337,474 shs
LXRX Lexicon Pharmaceuticals	$1.18 +9.3%	$0.75	$0.28 ▼ $2.45	$426.56M	1.13	6.87 million shs	3.04 million shs
XENE Xenon Pharmaceuticals	$32.60 +1.2%	$31.79	$26.74 ▼ $46.00	$2.50B	1.1	638,065 shs	618,806 shs
ZIOP ZIOPHARM Oncology		$1.08	$0.77 ▼ $5.95	$187.12M	1.71	2.01 million shs	2.13 million shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLUSF BELLUS Health	0.00%	0.00%	0.00%	0.00%	0.00%
KPTI Karyopharm Therapeutics	+4.84%	+12.77%	+8.66%	+11.97%	-66.30%
LXRX Lexicon Pharmaceuticals	+9.26%	+35.20%	+75.73%	+130.42%	-40.40%
XENE Xenon Pharmaceuticals	+1.21%	+2.42%	-0.49%	-1.30%	-24.04%
ZIOP ZIOPHARM Oncology	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BLUSF BELLUS Health	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KPTI Karyopharm Therapeutics	4.0215 of 5 stars	3.5	0.0	0.0	4.6	2.9	2.5	0.6
LXRX Lexicon Pharmaceuticals	2.406 of 5 stars	3.2	3.0	0.0	0.0	1.5	2.5	0.6
XENE Xenon Pharmaceuticals	3.6232 of 5 stars	4.5	4.0	0.0	0.0	2.2	2.5	0.0
ZIOP ZIOPHARM Oncology	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BLUSF BELLUS Health	0.00	N/A	N/A	N/A
KPTI Karyopharm Therapeutics	3.00	Buy	$37.40	684.07% Upside
LXRX Lexicon Pharmaceuticals	2.40	Hold	$3.67	210.73% Upside
XENE Xenon Pharmaceuticals	3.00	Buy	$54.82	68.15% Upside
ZIOP ZIOPHARM Oncology	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest KPTI, BLUSF, LXRX, ZIOP, and XENE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/11/2025	KPTI Karyopharm Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$27.00
6/24/2025	LXRX Lexicon Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
5/14/2025	XENE Xenon Pharmaceuticals	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$55.00
5/13/2025	KPTI Karyopharm Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$34.00 ➝ $33.00
5/13/2025	KPTI Karyopharm Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$5.00 ➝ $10.00
5/13/2025	KPTI Karyopharm Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$54.00 ➝ $42.00
5/13/2025	XENE Xenon Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$50.00 ➝ $47.00
5/13/2025	XENE Xenon Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$58.00 ➝ $55.00
5/13/2025	XENE Xenon Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$53.00 ➝ $53.00
5/13/2025	XENE Xenon Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$55.00 ➝ $55.00
5/13/2025	XENE Xenon Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$60.00 ➝ $55.00

(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BLUSF BELLUS Health	$30K	0.00	N/A	N/A	$0.25 per share	0.00
KPTI Karyopharm Therapeutics	$145.24M	0.28	N/A	N/A	($22.10) per share	-0.22
LXRX Lexicon Pharmaceuticals	$31.21M	13.67	N/A	N/A	$0.40 per share	2.95
XENE Xenon Pharmaceuticals	$9.43M	265.26	N/A	N/A	$9.90 per share	3.29
ZIOP ZIOPHARM Oncology	N/A	N/A	N/A	N/A	$0.58 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BLUSF BELLUS Health	-$7.01M	-$0.10	N/A	N/A	N/A	-49,910.34%	-48.37%	-45.25%	N/A
KPTI Karyopharm Therapeutics	-$76.42M	-$13.26	N/A	N/A	N/A	-43.99%	N/A	-35.95%	8/5/2025 (Estimated)
LXRX Lexicon Pharmaceuticals	-$200.40M	-$0.51	N/A	N/A	N/A	-568.04%	-103.16%	-54.95%	7/30/2025 (Estimated)
XENE Xenon Pharmaceuticals	-$234.33M	-$3.23	N/A	N/A	N/A	N/A	-32.44%	-30.84%	8/14/2025 (Estimated)
ZIOP ZIOPHARM Oncology	-$79.98M	-$0.43	N/A	N/A	N/A	N/A	-92.84%	-72.46%	N/A

Latest KPTI, BLUSF, LXRX, ZIOP, and XENE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	LXRX Lexicon Pharmaceuticals	-$0.07	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	KPTI Karyopharm Therapeutics	-$3.72	N/A	N/A	N/A	$37.92 million	N/A
5/13/2025	Q1 2025	LXRX Lexicon Pharmaceuticals	-$0.10	-$0.07	+$0.03	-$0.07	$1.26 million	$1.26 million
5/12/2025	Q1 2025	KPTI Karyopharm Therapeutics	-$4.21	-$2.77	+$1.44	-$2.77	$35.12 million	$30.02 million
5/12/2025	Q1 2025	XENE Xenon Pharmaceuticals	-$0.90	-$0.83	+$0.07	-$0.83	$1.64 million	$7.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BLUSF BELLUS Health	N/A	N/A	N/A	N/A	N/A
KPTI Karyopharm Therapeutics	N/A	N/A	N/A	N/A	N/A
LXRX Lexicon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
XENE Xenon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ZIOP ZIOPHARM Oncology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BLUSF BELLUS Health	N/A	13.87	13.87
KPTI Karyopharm Therapeutics	N/A	1.33	1.28
LXRX Lexicon Pharmaceuticals	0.48	2.22	2.22
XENE Xenon Pharmaceuticals	N/A	17.66	17.66
ZIOP ZIOPHARM Oncology	0.18	3.43	3.43

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BLUSF BELLUS Health	N/A
KPTI Karyopharm Therapeutics	66.44%
LXRX Lexicon Pharmaceuticals	74.70%
XENE Xenon Pharmaceuticals	95.45%
ZIOP ZIOPHARM Oncology	51.03%

Insider Ownership

Company	Insider Ownership
BLUSF BELLUS Health	24.17%
KPTI Karyopharm Therapeutics	2.75%
LXRX Lexicon Pharmaceuticals	13.90%
XENE Xenon Pharmaceuticals	5.52%
ZIOP ZIOPHARM Oncology	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BLUSF BELLUS Health	10	159.12 million	N/A	Not Optionable
KPTI Karyopharm Therapeutics	380	8.64 million	8.40 million	Optionable
LXRX Lexicon Pharmaceuticals	140	361.49 million	311.25 million	Optionable
XENE Xenon Pharmaceuticals	210	76.73 million	72.50 million	Optionable
ZIOP ZIOPHARM Oncology	105	216.15 million	204.91 million	Optionable

KPTI, BLUSF, LXRX, ZIOP, and XENE Headlines

Recent News About These Companies

TCRT stock touches 52-week low at $1.62 amid market challenges

January 30, 2025 | msn.com

Best Global Universities for Oncology

September 11, 2024 | usnews.com

FDA fast-tracks Merck's cancer blockbuster-in-waiting

July 28, 2024 | pharmaphorum.comP

BMS signs $475m cancer immunotherapy deal with Dragonfly

July 23, 2024 | pharmaphorum.comP

Childhood Cancers

February 17, 2024 | curetoday.comC

Alx Oncology Holdings (ALXO)

February 10, 2024 | investing.com

Pediatric Hematology-Oncology Fellowship

February 5, 2024 | bcm.eduB

Alaunos Therapeutics: Other Events, Financial Statements And Exhibits

January 31, 2024 | cbonds.comC

CG Oncology Inc

January 31, 2024 | reuters.com

Oncology Nurses' Narratives About Ethical Dilemmas and Prognosis-Related Communication in Advanced Cancer Patients

December 21, 2023 | medscape.comM

Immuno-Oncology

December 19, 2023 | ajmc.comA

Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today?

December 18, 2023 | markets.businessinsider.com

Exploring Patient-Centered Handoffs in Surgical Oncology

December 10, 2023 | medscape.comM

Association of Community Cancer Centers

October 14, 2023 | ajmc.comA

Oncology News and Research

September 19, 2023 | news-medical.netN

WBSPH 2024 - Oncology

September 15, 2023 | newsweek.comN

Kris on Oncology

September 6, 2023 | medscape.comM

Gauging Ziopharm's Chances for Positive Sarcoma Drug Trial Results

August 29, 2023 | thestreet.com

Oncology Cases & Quizzes

August 14, 2023 | medscape.comM

Ziopharm’s palifosfamide fails in first-line STS…

June 20, 2023 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KPTI, BLUSF, LXRX, ZIOP, and XENE Company Descriptions

BELLUS Health OTCMKTS:BLUSF

BELLUS Health, Inc. is a biopharmaceutical development company, which engages in the research and development of products that provide health solutions and address critical unmet medical needs. Its products include BLU-5937, KIACTA, AMO-01, and ALZ-801. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.

Karyopharm Therapeutics NASDAQ:KPTI

$4.77 +0.22 (+4.84%)

Closing price 07/14/2025 04:00 PM Eastern

Extended Trading

$4.77 0.00 (0.00%)

As of 07/14/2025 07:31 PM Eastern

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Lexicon Pharmaceuticals NASDAQ:LXRX

$1.18 +0.10 (+9.26%)

Closing price 07/14/2025 04:00 PM Eastern

Extended Trading

$1.16 -0.02 (-2.12%)

As of 07/14/2025 07:59 PM Eastern

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Xenon Pharmaceuticals NASDAQ:XENE

$32.60 +0.39 (+1.21%)

Closing price 07/14/2025 04:00 PM Eastern

Extended Trading

$32.59 -0.01 (-0.03%)

As of 07/14/2025 04:27 PM Eastern

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

ZIOPHARM Oncology NASDAQ:ZIOP

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline includes Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time